سعر انتيفين 3 مليون وحدة دولية فيال 2022

Intefen: recombinant interferon alfa-2a, 3 million IU per vial (Shenyang Sunshine Pharmaceutical, China; Egyptian agent Egyptian Pharmex). Whether the vial holds a powder or a solution was not confirmed.

• Most patients develop a flu-like syndrome (fatigue, fever, chills, loss of appetite, myalgia, headache, arthralgia, sweating), usually attenuated by paracetamol. About two-thirds of cancer patients had anorexia and half had nausea; cardiovascular and pulmonary disorders were seen in about one-fifth of cancer patients.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)

• Hypersensitivity to interferon alfa-2a or to any excipient; pre-existing severe cardiac disease; severe renal, hepatic or myeloid insufficiency; uncontrolled epilepsy or CNS compromise.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)
• Chronic hepatitis with advanced decompensated liver disease or cirrhosis; chronic hepatitis in patients receiving or recently treated with immunosuppressive agents.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)

• Should be administered under the supervision of a qualified physician experienced in its use. Severe psychiatric adverse reactions, including depression, suicidal ideation and suicide attempts, may occur; patients should be monitored.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)
• Fever may reflect the flu-like syndrome but serious bacterial, viral or fungal infections must be excluded, especially in neutropenic patients. Retinopathy has been reported; an eye examination is recommended before treatment, particularly in patients with diabetes or hypertension. Hyperglycaemia, myelosuppression and autoimmune disorders (including thyroid dysfunction) may occur.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)

• TheophyllineInterferon alfa-2a has been reported to reduce theophylline clearance.ANSM - Base de donnees publique / ecodex (France)
• CNS-active drugs; myelosuppressive, neurotoxic or cardiotoxic agentsPossible additive neurological, haematological or cardiac toxicity; use caution with concomitant centrally acting drugs and drugs previously or concurrently given that affect these systems.ANSM - Base de donnees publique / ecodex (France)

• No adequate data in pregnant women; an abortifacient effect was seen in rhesus monkeys at doses far above the clinical dose. Use during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus. When combined with ribavirin, pregnancy is contraindicated and effective contraception is required (see ribavirin SmPC).General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)
• No data on excretion into breast milk; the choice between stopping breastfeeding and stopping treatment depends on the therapeutic benefit to the mother.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)

• Regular full blood counts before and during treatment; in patients with a history of autoimmune disorders, monitor for autoimmune symptoms, autoantibodies and TSH; eye examination before treatment in patients with diabetes or hypertension; measure blood glucose in patients with symptoms of hyperglycaemia.General active-ingredient information · ANSM - Base de donnees publique / ecodex (France)

English text not available for this section.